Neonatal Effects of Maternal Magnesium Sulphate in Late Preterm and Term Pregnancies
- 32 Downloads
To compare the clinical, obstetric and neonatal parameters between patients with > 34-week gestation having severe preeclampsia receiving magnesium sulphate and those with > 34-week gestation with preeclampsia but not receiving magnesium sulphate.
Materials and Methods
Single-centre prospective study studied 60 patients in each of the two groups. Magnesium sulphate was administered by Pritchard regimen as per standard protocol. Standard obstetric management was followed for both groups. In the severe preeclampsia/eclampsia group, maternal blood sample was analysed for serum magnesium levels. The duration of exposure, the amount of magnesium sulphate received and time elapsed between last dose of magnesium sulphate and delivery were all noted. Neonatal assessment was done. The various parameters including age, parity, blood pressure, mode of termination of pregnancy, NICU admission rate, incidence of hypotonia in the newborn and other neonatal parameters were tabulated and compared.
The two groups were comparable with respect to age and parity. Need for induction of labour was higher in the group with severe preeclampsia/eclampsia. Rate of LSCS and birth weights were comparable between the two groups. NICU admission rate and incidence of hypotonia were higher in those who received magnesium sulphate. Amount of magnesium sulphate received and total duration of magnesium sulphate did not correlate with NICU admission rates.
Neonatal morbidity, in terms of higher NICU admission rates and hypotonia, is higher in patients receiving magnesium sulphate.
KeywordsMagnesium sulphate Neonatal Neuroprotection Hypotonia NICU admission
The authors sincerely acknowledge the contribution of Late Dr Jayant S Rege towards this study.
Compliance with Ethical Standards
Conflict of interest
All the authors declare that they have no conflict of interest.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Since it was a retrospective review of records, no informed consent was obtained from any patients for being included in the study. This article does not contain any studies with animal subjects.
- 1.Bain ES, Middleton PF, Crowther CA. Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review. BMC Pregnancy Childbirth. BioMed Central 2013;13:195. http://www.ncbi.nlm.nih.gov/pubmed/24139447.
- 4.Drinkwater J. Magnesium sulphate for pre-eclampsia: care of the neonate. Pract Midwife. 2011;14(11):17–9.Google Scholar
- 5.Greenberg MB, Penn AA, Thomas LJ et al. Neonatal medical admission in a term and late-preterm cohort exposed to magnesium sulfate. Am J Obstet Gynecol. 2011; 204(6):515.e1–515.e7. http://www.ncbi.nlm.nih.gov/pubmed/21376302.
- 12.Drassinower D, Friedman AM, Levin H et al. Does magnesium exposure affect neonatal resuscitation? Am J Obstet Gynecol. 2015; 213(3):424.e1–424.e5. http://www.ncbi.nlm.nih.gov/pubmed/26026919.
- 17.Brookfield KF, Su F, Elkomy MH et al. Pharmacokinetics and placental transfer of magnesium sulfate in pregnant women. Am J Obstet Gynecol. 2016; 214(6):737.e1–737.e9. http://www.ncbi.nlm.nih.gov/pubmed/26767791.
- 18.Long Q, Oladapo O, Leathersich S et al. Clinical practice patterns on the use of magnesium sulphate for treatment of pre-eclampsia and eclampsia: a multi-country survey. BJOG. 2016. http://www.ncbi.nlm.nih.gov/pubmed/27885772.